The main idea here is that USP 800 allows a risk-based, alternative approach to handling hazardous drugs when a proper assessment demonstrates adequate containment. An AOR/alternative handling approach can justify not applying every USP 800 requirement to specific low-risk forms. The best answer identifies the drugs that may be exempt when such an AOR is performed: the final dosage forms of compounded hazardous-drug preps and conventionally manufactured hazardous-drug products that do not require any further manipulations beyond counting or repackaging. Since these forms aren’t being prepared or altered to create new dosage forms, their exposure potential is minimal, so with a documented AOR, they can be managed using containment and practices appropriate to that assessed risk rather than the full USP 800 suite. Other choices aren’t correct because USP 800 isn’t a blanket rule for all HDs regardless of AOR, and AOR is a sanctioned option you can use to tailor containment for certain forms. The notion that AOR is not allowed is incorrect, and while AOR can be used for other HDs, the statement about which drugs don’t have to follow USP 800 specifically points to those final dosage forms that require no further manipulation beyond counting or repackaging.

The API is the substance intended for use in compounding that becomes the active ingredient with pharmacological activity. This means it is the specific drug component in a preparation that produces the therapeutic effect. Solvents, preservatives, and colorants do not have pharmacological activity themselves, so they are not considered the API—they’re inactive ingredients or excipients used to formulate, preserve, or identify the final product. For example, the active drug in a compounded suspension is the API, while the solvent or vehicle carries it, and any preservative or dye serves a supportive role rather than providing the therapeutic effect.

Water-containing topical and mucosal liquids have water in the formulation, which allows microorganisms to grow if the product sits for too long. Because of that risk, the beyond-use date is limited to 30 days, providing a safe, practical window to use the product before microbial growth becomes a concern. Extending beyond 30 days would increase the chance of contamination or infection, while shorter time frames would unnecessarily shorten usable life without added safety benefits. For products without water, or for certain non-aqueous formulations, longer BUDs may apply, but for water-containing topical and mucosal liquids the standard is not later than 30 days.

The rule here focuses on two linked requirements: you must document any alternative containment strategies used in the AOR, and you must review the AOR at least every 12 months to ensure it remains appropriate and effective. Documenting the alternatives provides traceability and justification for deviating from standard containment, while the annual review keeps the AOR current with changes in procedures, equipment, and regulations. Because both elements are required, the statement that includes both documentation of alternative containment strategies and a yearly review is the true one.